However, we found that the residual transcriptional activity of TP53 mutations toward CDKN1A/p21 and other TP53 target genes significantly varied among the different TP53mutated B-CLL patient cell samples. The gene discussed is CDKN1A; the disease is B-cell chronic lymphocytic leukemia.